Natarajan Sethuraman Sells 2,700 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 2,700 shares of Entrada Therapeutics stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $20.04, for a total value of $54,108.00. Following the completion of the transaction, the insider now owns 160,888 shares of the company’s stock, valued at approximately $3,224,195.52. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Natarajan Sethuraman also recently made the following trade(s):

• On Monday, November 11th, Natarajan Sethuraman sold 1,409 shares of Entrada Therapeutics stock. The shares were sold at an average price of $20.01, for a total value of $28,194.09.
• On Wednesday, October 16th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The stock was sold at an average price of $18.00, for a total transaction of $10,800.00.
• On Monday, September 9th, Natarajan Sethuraman sold 2,642 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.09, for a total transaction of $39,867.78.
• On Friday, September 6th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.24, for a total transaction of $9,144.00.

Entrada Therapeutics Stock Up 0.9 %

NASDAQ TRDA traded up $0.17 during trading hours on Wednesday, hitting $19.96. The company’s stock had a trading volume of 219,660 shares, compared to its average volume of 107,128. The stock has a fifty day moving average of $16.53 and a 200 day moving average of $15.83. The firm has a market capitalization of $746.90 million, a P/E ratio of 12.55 and a beta of -0.26. Entrada Therapeutics, Inc. has a twelve month low of $10.75 and a twelve month high of $20.49.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The firm had revenue of $94.69 million for the quarter, compared to analysts’ expectations of $55.00 million. On average, analysts predict that Entrada Therapeutics, Inc. will post 1.07 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company grew its holdings in shares of Entrada Therapeutics by 3.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock valued at $814,000 after buying an additional 2,146 shares during the period. US Bancorp DE bought a new position in Entrada Therapeutics during the third quarter worth about $42,000. Acadian Asset Management LLC bought a new stake in shares of Entrada Therapeutics in the first quarter worth about $79,000. Rhumbline Advisers raised its position in shares of Entrada Therapeutics by 25.3% during the second quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock worth $526,000 after purchasing an additional 7,452 shares during the period. Finally, SG Americas Securities LLC bought a new position in shares of Entrada Therapeutics during the 3rd quarter valued at about $156,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. HC Wainwright upped their price objective on Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Oppenheimer upped their price target on Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research note on Wednesday, November 6th.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.